Last reviewed 2026-04-20 · How we verify

Fluzone® 2012-2013 Formula NDC No 498281-012-50

Stanford University · FDA-approved active Biologic Quality 2/100

Fluzone® 2012-2013 Formula NDC No 498281-012-50 is a Biologic drug developed by Stanford University. It is currently FDA-approved. Also known as: Trivalent inactivated influenza vaccine (TIV).

Fluzone® 2012-2013 Formula, marketed by Stanford University, is a seasonal influenza vaccine with a key composition patent expiring in 2028. The primary competitive advantage lies in its established market presence and trusted efficacy profile. The primary risk is the potential increase in competition following the patent expiry in 2028.

At a glance

Generic name	Fluzone® 2012-2013 Formula NDC No 498281-012-50
Also known as	Trivalent inactivated influenza vaccine (TIV)
Sponsor	Stanford University
Modality	Biologic
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

The Influence of Chronic CMV Infection on Influenza Vaccine Responses (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Fluzone® 2012-2013 Formula NDC No 498281-012-50 CI brief — competitive landscape report
Fluzone® 2012-2013 Formula NDC No 498281-012-50 updates RSS · CI watch RSS
Stanford University portfolio CI

Frequently asked questions about Fluzone® 2012-2013 Formula NDC No 498281-012-50

What is Fluzone® 2012-2013 Formula NDC No 498281-012-50?

Fluzone® 2012-2013 Formula NDC No 498281-012-50 is a Biologic drug developed by Stanford University.

Who makes Fluzone® 2012-2013 Formula NDC No 498281-012-50?

Fluzone® 2012-2013 Formula NDC No 498281-012-50 is developed and marketed by Stanford University (see full Stanford University pipeline at /company/stanford-university).

Is Fluzone® 2012-2013 Formula NDC No 498281-012-50 also known as anything else?

Fluzone® 2012-2013 Formula NDC No 498281-012-50 is also known as Trivalent inactivated influenza vaccine (TIV).

What development phase is Fluzone® 2012-2013 Formula NDC No 498281-012-50 in?

Fluzone® 2012-2013 Formula NDC No 498281-012-50 is FDA-approved (marketed).

Manufacturer: Stanford University — full pipeline
Also known as: Trivalent inactivated influenza vaccine (TIV)
Compare: Fluzone® 2012-2013 Formula NDC No 498281-012-50 vs similar drugs
Pricing: Fluzone® 2012-2013 Formula NDC No 498281-012-50 cost, discount & access